CD274 and non-small cell lung carcinoma: In conclusion, the results of our retrospective observational study of pembrolizumab monotherapy in first-line metastatic NSCLC with PD-L1 ≥ 50% are consistent with previously reported real-world studies and the results of Keynote-024.